Lung cancer articles from across Nature Portfolio Lung cancer arises in tissues of the lung, usually in the cells lining air passages. The two main types are small-cell lung cancer and non-small ...

If you use an at-home test for lung cancer, be sure to review the results with a doctor. They can use the results of your test along with other clinical tests, such as imaging and a biopsy, to ...

Dr. Drew Harris, a pulmonologist, shows an CT scan of a patient with black lung. Once a month, he drives more than 300 miles to St. Charles, Va., to see black lung patients.

A downside to CT screening for lung cancer is that the test can have false-positive findings that lead to unnecessary medical procedures. For instance, your doctor might spot a nodule that looks ...

Send comments and news tips to [email protected]. Cite this: ‘Popcorn Lung’: Connecting the Dots to a Historically Difficult Diagnosis - Medscape - June 18, 2025.

Introduction The promise of benefits from lung cancer screening is tempered by the false positive rate and the need to perform diagnostic procedures to determine the aetiology of the solitary ...

Small-cell lung cancer articles from across Nature Portfolio Small-cell lung cancer is a highly malignant form of lung cancer, also known as oat-cell carcinoma, that accounts for approximately 15% ...

Whatever the cause, it's important to find lung cancer early when it's curable. That's why the Lung Force walk comes together every year to raise awareness. "It is very important.

Lung cancer commonly spreads to organs such as the brain and bones. Learn why — and how to spot signs and symptoms of metastatic lung cancer.

Lung cancer is the most common cancer worldwide and the leading cause of cancer death. In 2022, about 2.5 million people were diagnosed with the disease and more than 1.8 million died.

DULUTH — Since being diagnosed with Stage 4 lung cancer in November 2024, running has taken on a new meaning for 37-year-old Caitlin Quinn. A mother of three children between 2 and 7, running ...

Johnson & Johnson has projected its lung cancer drug Rybrevant could achieve $5 billion in peak revenue. At the recent ASCO annual meeting, J&J executive Joshua Bauml explained his company’s ...